Trial Profile
A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Gemcitabine
- Indications Biliary cancer; Bladder cancer; Carcinoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors NanoCarrier
- 27 Feb 2020 Status changed from active, no longer recruiting to completed.
- 22 Oct 2019 This trial has been completed in Poland, according to European Clinical Trials Database. (2018-12-21)
- 25 Apr 2019 Status changed from recruiting to active, no longer recruiting.